A prospective study of in-office diagnostic vitreous sampling in patients with vitreoretinal pathology

Retina

Volumn 29, Issue 7, 2009, Pages 1032-1035

  Pfahler, Scott M ^a   Brandford, Angela N ^a   Glaser, Bert M ^a  

^a National Retina Institute   (United States)

Author keywords

Age related macular degeneration; Diagnostic vitreous sampling; In office vitreous sample; Intravitreal injection; Safety; Vitreous proteome

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE SODIUM PHOSPHATE; GATIFLOXACIN; MOXIFLOXACIN; PREDNISOLONE ACETATE; STEROID; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CENTRAL RETINA ARTERY OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CLINICAL TRIAL; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DIAGNOSTIC PROCEDURE; EYE INFLAMMATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OCULAR HISTOPLASMOSIS; PATIENT SAFETY; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; VITREORETINOPATHY; VITREOUS BODY; VITREOUS HEMORRHAGE; VITREOUS SAMPLING;

ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; ENDOPHTHALMITIS; EYE DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; PHYSICIANS' OFFICES; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; RETINAL DETACHMENT; RETINAL DISEASES; SPECIMEN HANDLING; VITREOUS BODY; VITREOUS HEMORRHAGE;

EID: 68249115028     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181a2c1eb     Document Type: Article

References (9)

1. Davaluri G, Espina V, Petricoin E, et al. Activated VEGF receptor shed into the vitreous in eyes with wet AMD: a new class of biomarkers in the vitreous with potential for predicting the treatment timing and monitoring response. Arch Ophthalmol, in press.
2. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibuizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431. (Pubitemid 44511557)
3. Garg S, Brod R, Kim D, et al. Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration. Clin Experiment Ophthalmol 2008;36:252-256. (Pubitemid 351560274)
4. Fintak DR, Shah GV, Blinder KJ, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibuizumab. Retina 2008;28:1395-1399.
5. Kim JE, Mantravadi AV, Hur EY, et al. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol 2008;146:930-934.e1.
6. Harisprasad SM, Shah GK, Blinder KJ. Short-term intraocular pressure trends following intravitreal pegaptanib (Macugen) injection. Am J Ophthalmol 2006;141:200-201. (Pubitemid 43016199)
7. Lee EW, Hariprasad SM, Mieler WF, et al. Short-term intraocular pressure trends pressure trends after intravitreal triamcinolone injection. Am J Ophthalmol 2007;143:365-367. (Pubitemid 46136143)
8. Falkenstein IA, Cheng L, Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin). Retina 2007;27:1044-1047. (Pubitemid 350304005)
9. Benz MS, Albini TA, Holz ER, et al. Short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide. Ophthalmology 2006;113:1174-1178. (Pubitemid 43947221)